NitiLoop

Company Overview

Snapshot

Founded in January 2011, NitiLoop operated with 1–10 employees and was acquired by Microbot Medical in October 2022. The company developed the NovaCross microcatheter, which received FDA 510(k) clearance in May 2015 for guidewire access support.

Business overview

NitiLoop is a Health Tech & Life Sciences company specializing in Medical Devices, particularly vascular support microcatheters. The company developed the NovaCross, a microcatheter designed to enable guidewire positioning and distal support with an extendable segment. This proprietary platform is also intended for additional products targeting below-the-knee and embolotherapy applications, liver cancer treatment with chemotherapy, and radiation bead injection through microcatheters. NitiLoop operates in the healthcare industry, serving providers in the cardiology and surgical fields.

Strategic signal

The acquisition of NitiLoop by Microbot Medical in October 2022 signals a strategic consolidation within the medical device sector, particularly for microcatheter technologies. This move indicates Microbot Medical's intent to integrate NitiLoop's FDA-cleared assets, including the NovaCross microcatheter, into its portfolio, potentially expanding its market reach and technological capabilities in vascular interventions. For investors, this highlights the value placed on innovative, regulatory-approved medical devices and the ongoing trend of larger players acquiring specialized technologies to enhance their offerings.

Company Intelligence Q&A

What was a significant corporate event for NitiLoop?

NitiLoop was acquired by Microbot Medical in October 2022, leading to its inactive status.

When did NitiLoop receive FDA clearance for its NovaCross Microcatheter?

NitiLoop announced FDA 510(k) clearance for its NovaCross Microcatheter in May 2015, for support of guidewire access to discrete regions of the coronary and peripheral vasculature.

Which investors participated in NitiLoop's funding round in May 2015?

In May 2015, NitiLoop received funding from Accelmed and Access Medical Ventures.

When did NitiLoop receive additional FDA clearance for its Nova Cross Extreme and Nova Cross BTK Microcatheter?

In October 2017, NitiLoop announced FDA 510(k) clearance for its Nova Cross Extreme and Nova Cross BTK Microcatheter for support of guidewire access to discrete regions of the coronary and peripheral vasculature.

When did NitiLoop's NovaCross earn FDA clearance for treating Chronic Total Occlusion (CTO)?

In April 2020, NitiLoop's NovaCross earned FDA clearance for treating Chronic Total Occlusion (CTO) prior to PTCA or stent intervention.